Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Acomplia

Known as: Zimulti 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Acomplia was ordered over the internet resulting in the delivery of counterfeit Acomplia and imitation products. The tablets were… Expand
Highly Cited
2009
Highly Cited
2009
Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have… Expand
Review
2008
Review
2008
The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia… Expand
2008
2008
The cannabinoid and serotonin systems modulate feeding behavior in humans and laboratory animals. The present study assessed… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
Rimonabant (AcompliaTM, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved for the treatment of… Expand
Review
2006
Review
2006
Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized… Expand
Review
2006
Review
2006
Rimonabant (SR141716, Acomplia) has been described as an antagonist/inverse agonist at the cannabinoid receptor type 1 (CB1). It… Expand
Highly Cited
2005
Highly Cited
2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory… Expand
Review
2005
Review
2005
Over past centuries, Cannabis sativa (Delta(9)-tetrahydrocannabinol being the principal active ingredient) has been used… Expand
Review
2005
Review
2005
The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus… Expand